Tristan T Timbrook1,2, Jacob B Morton1,2, Kevin W McConeghy3, Aisling R Caffrey1,3,2, Eleftherios Mylonakis4, Kerry L LaPlante1,3,2. 1. Rhode Island Infectious Diseases Research Program, Providence Veterans Affairs Medical Center. 2. College of Pharmacy, University of Rhode Island, Kingston. 3. Center of Innovation in Long Term Services and Supports, Providence Veterans Affairs Medical Center. 4. Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence.
Abstract
BACKGROUND: Previous reports on molecular rapid diagnostic testing (mRDT) do not consistently demonstrate improved clinical outcomes in bloodstream infections (BSIs). This meta-analysis seeks to evaluate the impact of mRDT in improving clinical outcomes in BSIs. METHODS: We searched PubMed, CINAHL, Web of Science, and EMBASE through May 2016 for BSI studies comparing clinical outcomes between mRDT and conventional microbiology methods. RESULTS: Thirty-one studies were included with 5920 patients. The mortality risk was significantly lower with mRDT than with conventional microbiology methods (odds ratio [OR], 0.66; 95% confidence interval [CI], .54-.80), yielding a number needed to treat of 20. The mortality risk was slightly lower with mRDT in studies with antimicrobial stewardship programs (ASPs) (OR, 0.64; 95% CI, .51-.79), and non-ASP studies failed to demonstrate a significant decrease in mortality risk (0.72; .46-1.12). Significant decreases in mortality risk were observed with both gram-positive (OR, 0.73; 95% CI, .55-.97) and gram-negative organisms (0.51; .33-.78) but not yeast (0.90; .49-1.67). Time to effective therapy decreased by a weighted mean difference of -5.03 hours (95% CI, -8.60 to -1.45 hours), and length of stay decreased by -2.48 days (-3.90 to -1.06 days). CONCLUSIONS: For BSIs, mRDT was associated with significant decreases in mortality risk in the presence of a ASP, but not in its absence. mRDT also decreased the time to effective therapy and the length of stay. mRDT should be considered as part of the standard of care in patients with BSIs. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Previous reports on molecular rapid diagnostic testing (mRDT) do not consistently demonstrate improved clinical outcomes in bloodstream infections (BSIs). This meta-analysis seeks to evaluate the impact of mRDT in improving clinical outcomes in BSIs. METHODS: We searched PubMed, CINAHL, Web of Science, and EMBASE through May 2016 for BSI studies comparing clinical outcomes between mRDT and conventional microbiology methods. RESULTS: Thirty-one studies were included with 5920 patients. The mortality risk was significantly lower with mRDT than with conventional microbiology methods (odds ratio [OR], 0.66; 95% confidence interval [CI], .54-.80), yielding a number needed to treat of 20. The mortality risk was slightly lower with mRDT in studies with antimicrobial stewardship programs (ASPs) (OR, 0.64; 95% CI, .51-.79), and non-ASP studies failed to demonstrate a significant decrease in mortality risk (0.72; .46-1.12). Significant decreases in mortality risk were observed with both gram-positive (OR, 0.73; 95% CI, .55-.97) and gram-negative organisms (0.51; .33-.78) but not yeast (0.90; .49-1.67). Time to effective therapy decreased by a weighted mean difference of -5.03 hours (95% CI, -8.60 to -1.45 hours), and length of stay decreased by -2.48 days (-3.90 to -1.06 days). CONCLUSIONS: For BSIs, mRDT was associated with significant decreases in mortality risk in the presence of a ASP, but not in its absence. mRDT also decreased the time to effective therapy and the length of stay. mRDT should be considered as part of the standard of care in patients with BSIs. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Allison M Porter; Christopher M Bland; Henry N Young; David R Allen; Sabrina R Croft; R Ellen Gayheart; Parks W Miller; Rachel J Musgrove; Emilee M Robertson; Geneen M Gibson Journal: Antimicrob Agents Chemother Date: 2018-12-21 Impact factor: 5.191
Authors: Poornima Ramanan; Alexandra L Bryson; Matthew J Binnicker; Bobbi S Pritt; Robin Patel Journal: Clin Microbiol Rev Date: 2017-11-15 Impact factor: 26.132
Authors: K R Rivard; V Athans; S W Lam; S M Gordon; G W Procop; S S Richter; E Neuner Journal: Eur J Clin Microbiol Infect Dis Date: 2017-05-23 Impact factor: 3.267
Authors: Gary V Doern; Karen C Carroll; Daniel J Diekema; Kevin W Garey; Mark E Rupp; Melvin P Weinstein; Daniel J Sexton Journal: Clin Microbiol Rev Date: 2019-10-30 Impact factor: 26.132